South Korea Agrees to Produce Russia's COVID-19 Vaccine

GL Rapha, one of South Korea's leading biotechnology companies, including a subsidiary of Hankook Korus Pharm, announced an agreement to manufacture in the country more than 150 million doses of the Sputnik V vaccine candidate.

The Russian Direct Investment Fund (RDIF) press release issued on November 13, 2020, stated the parties intend to start Sputnik V production in December 2020 and begin deliveries of the vaccine for export in January 2021. More than 150 million doses of the Sputnik V vaccine produced in South Korea are scheduled to enter the global market.

According to RDIF, more than 50 countries have received applications for the purchase of over 1.2 billion doses of the Sputnik V vaccine.